-
Everything is Tuberculosis | Everything is Tuberculosis John Green Ebury Press pp 208 ISBN 9781529961423 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-19 Talha Burki
No Abstract
-
Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis Thorax (IF 9.0) Pub Date : 2025-05-19 Katie Bechman, Kathryn Biddle, Aitana Miracle, Kelly He, Mark Gibson, Mark D Russell, Sarah Walsh, Peter Brex, Amit S Patel, Katherine J Myall, Sam Norton, Surinder S Birring, James Galloway
Objectives Infliximab, an anti-TNF agent, is used to treat sarcoidosis that does not respond to corticosteroids or second-line agents. The efficacy of other anti-TNF agents, non-TNF biologics and targeted synthetic therapies remains unclear. This study aims to evaluate the role of these therapies in the management of multisystem sarcoidosis. Methods We conducted a systematic literature search to identify
-
Home NIV for COPD: the devil is in the detail Thorax (IF 9.0) Pub Date : 2025-05-19 Patrick Brian Murphy, Swapna Mandal
The data supporting the benefits of home non-invasive ventilation (NIV) in patients with severe chronic obstructive pulmonary disease (COPD) have been accumulating over the last decade. Historically, there was debate about the potential benefits of home NIV in this patient population, with early small-scale studies in specialist centres demonstrating physiological changes;1–3 however, these findings
-
Impact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models Thorax (IF 9.0) Pub Date : 2025-05-19 Jean Louis Pépin, Eleonore Herquelot, Helene Denis, Anne Josseran, Florent Lavergne, Adam Benjafield, Atul Malhotra, Janna Raphelson, Peter Cistulli, Aurelie Schmidt, Sebastien Bailly, Alain Palot, Arnaud Prigent
Rationale Chronic obstructive pulmonary disease (COPD) is the most common indication for domiciliary non-invasive ventilation (NIV), but long-term outcomes data are limited. Objective This multistate model analysis estimated the impact of NIV therapy continuation versus cessation on transitions between three different disease states. Methods Model data came from the French national health insurance
-
Dynamic oxygenation subgroup bringing new insights in ARDS: more predictive of outcomes and response to PEEP than static PaO2/FiO2 Thorax (IF 9.0) Pub Date : 2025-05-19 Yu Bai, Shengsong Chen, Haopu Yang, Xu Huang, Jingen Xia, Qingyuan Zhan
Background Acute respiratory distress syndrome (ARDS) is a rapidly evolving condition. Dynamic assessments using patient trajectories may provide novel insights into disease heterogeneity. The primary objective of this study was to develop and validate dynamic oxygenation subgroups of ARDS based on longitudinal arterial oxygen tension/fractional inspired oxygen (PaO2/FiO2) ratios from the day of ARDS
-
Classifying ARDS by dynamic or static oxygenation impairment or are other approaches needed for greater value Thorax (IF 9.0) Pub Date : 2025-05-19 Marcus J Schultz, Denise Battaglini, Prashant Nasa
In this issue, Bai et al present a novel approach to classifying acute respiratory distress syndrome (ARDS), analysing how oxygenation trajectories over the first days of ventilation relate to outcomes, rather than relying on a single static measurement.1 Using data from multiple databases, they applied group-based trajectory modelling to identify three distinct subgroups of patients based on the evolution
-
Smaller Airways or Bigger Lungs? Dysanapsis Etiotypes and Obstructive Pulmonary Physiology at Rest and During Exercise. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-19 Sophie É Collins,Dennis Jensen,Miranda Kirby,Devin B Phillips,Yannick Molgat-Seon,Darcy D Marciniuk,Stephanie Lovinsky-Desir,Brandie L Walker,Shawn D Aaron,Paul Hernandez,Wan C Tan,Jean Bourbeau,Benjamin M Smith
-
Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-19 Matthieu Legrand,Edouard Jullien,Antoine Kimmoun,Guillaume Geri,Hafid Ait-Oufella,Stanislas Abrard,Samuel Gaugain,Fanny Bounes,Philippe Guerci,Julien Pottecher,Matthieu Jamme,Yves Poncelin de Raucourt,Damien Barraud,Jean-Michel Constantin,William Juguet,Sigismond Lasocki,Romain Sonneville,Juliette Audibert,Gaëtan Plantefève,Olivier Ellrodt,Anne-Laure Fedou,Marc Leone,Laurent Lefebvre,Adrien Auvet,David
BACKGROUND Preclinical and preliminary clinical data suggest that Iloprost may improve tissue perfusion in septic shock. However, its effect on organ failure remains unclear. METHODS In this multicenter, double-blind, randomized controlled trial, adults with septic shock and persistent hypoperfusion (i.e. elevated capillary refill time and/or skin mottling) were randomized to receive a 48-hour intravenous
-
Airway Scaffolds for Emphysema-related Hyperinflation - Six-Month Results from the BREATHE Trial. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-19 Anand Tana,Arschang Valipour,Alvin Ing,Daniel P Steinfort,Christopher M Orton,Karin Klooster,Theresa Klemm,Jonathan P Williamson,Jemma J Christie,Justin L Garner,T David Koster,Kelly Welz,Marlies van Dijk,Martin L Mayse,Pallav L Shah,Dirk-Jan Slebos,
RATIONALE Despite advancements in emphysema treatment, high morbidity and mortality rates highlight the need for innovative therapies. A novel self-expanding nitinol airway scaffold was designed to alleviate lung hyperinflation by connecting emphysematous parenchyma with central bronchi, releasing trapped air. OBJECTIVES To assess the feasibility, safety, and initial outcomes of airway scaffolds in
-
Approach to the Evaluation and Management of Interstitial Lung Abnormalities. An Official American Thoracic Society Clinical Statement. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-19 Anna J Podolanczuk,Gary M Hunninghake,Kevin C Wilson,Yet H Khor,Fayez Kheir,Brandon Pang,Ayodeji Adegunsoye,Gretchen Cararie,Tamera J Corte,Jim Flanagan,Gunnar Gudmundsson,Lida P Hariri,Hiroto Hatabu,Stephen M Humphries,Bhavika Kaul,John S Kim,Melanie Konigshoff,Jonathan A Kropski,Joyce S Lee,Fengming Luo,David A Lynch,Fernando J Martinez,Sydney B Montesi,Yuben Moodley,Justin M Oldham,Sara Piciucchi
BACKGROUND There is growing interest in identifying early stages of interstitial lung disease (ILD) to improve patient outcomes. This document reviews updated evidence on interstitial lung abnormalities (ILA), provides suggestions for screening, evaluation, and management, proposes criteria for distinguishing ILA from ILD, and identifies research priorities. METHODS A committee of clinical and methodology
-
Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-18 Mohsen Sadatsafavi,Trung N Tran,Ghislaine Scelo,Ming-Ju Tsai,John Busby,Benjamin Emmanuel,Liam G Heaney,Christine Jenkins,Flavia Hoyte,Giorgio Walter Canonica,Rohit Katial,Enrico Heffler,Eileen Wang,Francesca Puggioni,Michael E Wechsler,Ledit R F Ardusso,Jorge Máspero,Martin Sivori,Cathy Emmas,Andrew N Menzies-Gow,Neda Stjepanovic,Sinthia Z Bosnic-Anticevich,Belinda Cochrane,Eve Denton,Peter G Gibson
RATIONALE Although clinical trials have documented the oral corticosteroid (OCS)-sparing effect of biologics in patients with severe asthma, little is known about whether this translates to a reduction of new-onset OCS-related adverse outcomes. OBJECTIVE To compare the risk of developing new-onset OCS-related adverse outcomes between biologic-initiators and non-initiators. METHODS This was a longitudinal
-
Innovative models of lung function across the lifespan Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-15 Sanja Stanojevic
No Abstract
-
General population-based lung function trajectories over the life course: an accelerated cohort study Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-15 Judith Garcia-Aymerich, Martí de las Heras, Anne-Elie Carsin, Simone Accordini, Alvar Agustí, Dinh Bui, Shyamali C Dharmage, James W Dodd, Ikenna Eze, Ulrike Gehring, Thorarinn Gislason, Raquel Granell, Medea Imboden, Carmen Íñiguez, Ayoung Jeong, Sarah Koch, Gerard H Koppelman, Bénédicte Leynaert, Erik Melén, Jennifer Perret, Rosa Faner
BackgroundLung function is a key determinant of health, but current knowledge on lung function growth and decline over the life course is based on fragmented, potentially biased data. We aimed to empirically derive general population-based life course lung function trajectories, and to identify breakpoints and plateaus. MethodsWe created an accelerated cohort by pooling data from eight general population-based
-
Human Sputum Microbiome Composition and Sputum Inflammatory Cell Profiles Are Altered with Controlled Wood Smoke Exposure as a Model for Wildfire Smoke. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-16 Catalina Cobos-Uribe,Radhika Dhingra,Martha A Almond,Neil E Alexis,David B Peden,Jeffrey Roach,Meghan E Rebuli
RATIONALE Wood smoke exposure is increasing worldwide due to the rise in wildfire events. Various studies have associated exposure to wildfire-derived smoke with adverse respiratory conditions. However, the mechanism by which this occurs is unknown. Previous studies using wood smoke as a model of wildfire smoke have focused on the respiratory immune response and have reported increased neutrophil percentage
-
Chest Imaging with a Collagen-Binding Probe - A Human Hydroxyproline Assay? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-16 Sarah L Khan,Daniel J Kass
-
Loss of Lung Function Led to Loss of Life During the COVID-19 Pandemic. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-16 Rachel L Eddy,Don D Sin
-
How I do it: Best practices for right heart catheterization in the diagnosis of pulmonary hypertension. Chest (IF 9.5) Pub Date : 2025-05-16 Yuri Matusov,Nicholas A Kolaitis,Dael Geft,Jacqueline DesJardin,Christopher Barnett,Antoine Hage,Teresa De Marco,Michael I Lewis
Right heart catheterization (RHC) is the gold standard for the diagnosis of pulmonary hypertension (PH). There are variations in practice and several pitfalls introducing errors in diagnosis that can significantly impact treatment. Errors in assessing the correct pulmonary artery wedge pressure (PAWP) can significantly affect accurate classification of patients with pulmonary hypertension, and lead
-
Association between a Recalled Positive Airway Pressure (PAP) Device and Obstructive Lung Disease: A Province-Based Study. Chest (IF 9.5) Pub Date : 2025-05-16 Tetyana Kendzerska,Robert Talarico,Marcus Povitz,Kenneth Blades,Constance Mackenzie,Andrea S Gershon,Najib T Ayas,Marta Kaminska,Mark Fenton,Kerry A McBrien,Steven Hawken,Diana Ratycz,Robert L Owens,Sachin R Pendharkar
BACKGROUND Limited real-world data exist on the health impacts of the Philips Respironics recall for positive airway pressure (PAP) devices. RESEARCH QUESTION What is the relationship between PAP device manufacturer and obstructive lung disease (OLD) development and progression? STUDY DESIGN AND METHODS We conducted a retrospective longitudinal study using Ontario health administrative databases (Canada)
-
Discriminative Accuracy of the Simplified Spirometry for Identifying Spirometry-defined Chronic Obstructive Pulmonary Disease in Community. Chest (IF 9.5) Pub Date : 2025-05-16 Fan Wu,Gaoying Tang,Zhishan Deng,Qi Wan,Kunning Zhou,Heshen Tian,Binwei Hao,Cuiqiong Dai,Zihui Wang,Siqi Zou,Xiulin Liao,Si Huang,Qiaorui Zhou,Yuyan Hou,Jincong Gan,Huixian Lin,Xianliang Zeng,Lifei Lu,Suyin Huang,Changli Yang,Shengtang Chen,Yongqing Huang,Shuqing Yu,Yumin Zhou,Pixin Ran
BACKGROUND Low spirometry testing rate for screening of chronic obstructive pulmonary disease (COPD) is partly attributed to complex procedures, stringent quality control requirements, and long examination times. Simplifying the spirometry protocol may increase the feasibility of COPD screening in community settings. RESEARCH QUESTION Does the simplified spirometry protocol have high diagnostic accuracy
-
Effect of viloxazine and trazodone in obstructive sleep apnoea: a randomised, placebo-controlled, cross-over study Thorax (IF 9.0) Pub Date : 2025-05-13 Atqiya Aishah, Molly Kim, Laura Gell, Daniel Vena, Ali Azarbarzin, Huy Pho, Daniel Norman, Joseph Ojile, Neda Esmaeili, Luigi Taranto-Montemurro, Andrew Wellman, Scott Sands, Ludovico Messineo
Introduction Combination of the noradrenergic atomoxetine with either the antimuscarinic aroxybutynin or trazodone has been shown to improve obstructive sleep apnoea (OSA) severity. However, atomoxetine may contribute to apnoea-cycling and reduced drug tolerability due to wake-promoting, especially in a subgroup (poor cytochrome 2D6 metabolisers leading to higher blood concentration of medication)
-
Oxygen therapy in early warning scores: a systematic review and meta-analysis Thorax (IF 9.0) Pub Date : 2025-05-13 Charlotte H Harrison, Phoebe Tupper, Stephen Gerry, Verena Michael, Jonathan P Bedford, Carolyn Smith, Chris Subbe, Oliver Redfern, Peter J Watkinson
Background Early warning systems (EWS) used across the world typically assign a fixed number of points to patients receiving supplemental oxygen, regardless of amount. This ordinal binary approach may fail to recognise deteriorating patients who have an increasing oxygen requirement with otherwise stable observations. It is unclear whether weighting oxygen beyond binary scoring improves recognition
-
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial Thorax (IF 9.0) Pub Date : 2025-05-13 Lennie Derde, Anthony C Gordon, Paul R Mouncey, Farah Al-Beidh, Kathryn M Rowan, Alistair D Nichol, Yaseen M Arabi, Djillali Annane, Abigail Beane, Richard Beasley, Marc J M Bonten, Charlotte A Bradbury, Frank M Brunkhorst, Adrian Buzgau, Meredith Buxton, Allen C Cheng, Nicola Cooper, Matthew Cove, Olaf L Cremer, Michelle A Detry, Eamon J Duffy, Lise J Estcourt, Mark Fitzgerald, James Galea, Herman
Introduction Tocilizumab improves outcomes in critically ill patients with COVID-19. Whether other immune-modulator strategies are equally effective or better is unknown. Methods We investigated treatment with tocilizumab, sarilumab, anakinra and no immune modulator in these patients. In this ongoing, adaptive platform trial in 133 sites in 9 countries, we randomly assigned patients with allocation
-
Severe community-acquired pneumonia (sCAP): advances in management and future directions Thorax (IF 9.0) Pub Date : 2025-05-13 Ignacio Martin-Loeches, Luis Felipe Reyes, Alejandro Rodriguez
Severe community-acquired pneumonia (sCAP) is a major global health challenge, with high morbidity and mortality, especially among patients requiring intensive care. Despite advancements in antimicrobial therapies and supportive care, sCAP remains a significant threat, particularly for those needing invasive mechanical ventilation or vasopressor support. Recent progress in diagnostics, therapeutics
-
Serotype 3 associated invasive pneumococcal disease in children: analysis of 15 years of Australian national surveillance data Thorax (IF 9.0) Pub Date : 2025-05-13 Nusrat Homaira, Jahidur Rahman Khan, Adam Jaffé
The 13-valent conjugate pneumococcal vaccine (13vPCV) replaced the 7vPCV in the Australian Immunisation Program in 2011 as a 3+0 schedule, updated to 2+1 schedule in 2018. We analysed national surveillance data to investigate the change in the incidence of pneumococcal serotype 3 (ST3) invasive pneumococcal disease (IPD) in preschool children. During 2009–2023 the incidence/100 000 children of ST3
-
Green respiratory healthcare: what really matters Thorax (IF 9.0) Pub Date : 2025-05-11 Gary Connett, Mary Slingo, Ian Sinha, Dame Julia Slingo
The BTS/SIGN/NICE have recently published updated guidance for the treatment of asthma.1 The guideline advises that inhaler choice should be based on the lowest environmental impact among suitable devices and provides a hyperlink to a decision aid informing patients about the relative carbon footprint of dry powder versus metered dose aerosol inhalers. The advice is consistent with much of the published
-
Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial Thorax (IF 9.0) Pub Date : 2025-05-11 Alexander G Mathioudakis, Andrew Higham, Sebastian Bate, Victoria Chatzimavridou-Grigoriadou, Pradeesh Sivapalan, Jens-Ulrik Stæhr Jensen, Tim Felton, Jørgen Vestbo, Dave Singh
Inhaled corticosteroids (ICSs) benefit patients with chronic obstructive pulmonary disease at high risk of exacerbations with raised blood eosinophil count (BEC). Emerging evidence suggests current smokers show a reduced response to ICS. This post-hoc analysis of the FLAME trial explored the impact of smoking status on the efficacy of long-acting beta-2 agonist (LABA)+ICS versus LABA+long-acting muscarinic
-
ChatGPT and Other Large Language Models for Parents' Questions About Childhood Asthma: A Comparative Study. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-15 Angéline Girault,Anaïs Le,Apolline Gonsard,Rola Abou Taam,Eytan Sarfati,Guillaume Lezmi,David Drummond
-
Guidelines without borders: the case for JAK inhibitors as the first-line immunomodulator COVID-19 treatment Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-13 Daniel A Sweeney, Andre C Kalil
No Abstract
-
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-13 Alain Amstutz, Stefan Schandelmaier, Hannah Ewald, Benjamin Speich, Johannes M Schwenke, Christof M Schönenberger, Stephan Schobinger, Thomas Agoritsas, Kay M Tomashek, Seema Nayak, Mat Makowski, Alejandro Morales-Ortega, David Bernal-Bello, Giovanni Pomponio, Alessia Ferrarini, Monireh Ghazaeian, Frances Hall, Simon Bond, María Teresa García-Morales, María Jiménez-González, Matthias Briel
BackgroundEvidence from randomised clinical trials (RCTs) of Janus kinase (JAK) inhibitors—compared with usual care or placebo—in adults treated in hospital for COVID-19 is conflicting. We aimed to evaluate the benefits and harms of JAK inhibitors compared with placebo or usual care and whether treatment effects differed between prespecified participant subgroups. MethodsFor this systematic review
-
A Telacebec-shaped Puzzle Piece in the Treatment of Mycobacterial Diseases. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-13 Bouke B C de Jong
-
Health and Utilization Burden of Obstructive Sleep Apnea among U.S. Active-Duty Military Personnel. Chest (IF 9.5) Pub Date : 2025-05-12 Emerson M Wickwire,Vincent F Capaldi,Jeph Herrin,Benoit Stryckman,Connie Thomas,Scott G Williams,J Kent Werner,Wendy Funk,Thomas Nassif,Jennifer S Albrecht
BACKGROUND Despite the significant health and economic burden associated with obstructive sleep apnea (OSA) among civilians, little is known about this burden among active-duty military personnel. RESEARCH QUESTION What is the health and utilization burden of OSA among active-duty service members in the United States? STUDY DESIGN AND METHODS Data were derived from the Military Data Repository (2016-2021)
-
Proteomic analysis of nasopharyngeal aspirate biomarkers for prematurity-related bronchopulmonary dysplasia. Chest (IF 9.5) Pub Date : 2025-05-12 Fernando Garrido-Muñoz,Alejandro Fernández-Vega,Rebeca Gregorio-Hernández,Marta Padín-Fontán,Mónica de Las Heras-Martín,Marta Teresa-Palacio,Paula Alonso-Quintela,Alberto Trujillo-Fagundo,Alba Pérez-Pérez,Marcelino Pumarada-Prieto,Jon Montero-Gato,Victoria Aldecoa-Bilbao,Ignacio Oulengo-Erroz,Mario Sánchez-Fernández,Almudena Alonso-Ojembarrena
BACKGROUND The high incidence of bronchopulmonary dysplasia (BPD) continues to be a problem among extremely low-gestational-age neonates (ELGANs). Recent improvements in next-generation proteomics have provided opportunities to obtain new perspectives on the early detection of BPD. In this study, our main objectives were to study the proteomes of patients by collecting nasopharyngeal aspirate (NPA)
-
Occupational respiratory harms: preventable, not inevitable Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-09
No Abstract
-
Lung Function Decline and Airflow Limitation Risk in Preserved Ratio Impaired Spirometry (PRISm) Subtypes by Smoking Status. Chest (IF 9.5) Pub Date : 2025-05-10 Cuiqiong Dai,Fan Wu,Jia Tian,Jiangyu Cui,Zhishan Deng,Heshen Tian,Peiyu Huang,Huajing Yang,Youlan Zheng,Zihui Wang,Shan Xiao,Xiang Wen,Lifei Lu,Ningning Zhao,Changli Yang,Shuqing Yu,Shengming Liu,Dali Wang,Xiaoping Wang,Jiachun Lu,Nanshan Zhong,Yumin Zhou,Pixin Ran
BACKGROUND PRISm is regarded as a COPD precursor, but whether this varies by smoking status remains unclear. RESEARCH QUESTION Are annual lung function decline and the risk of developing airflow limitation different among PRISm subtypes by smoking status? STUDY DESIGN AND METHODS 2850 participants from a 15-year population-based prospective cohort were included in this analysis. Participants were categorized
-
Little Big Issues in Brain-Lung Crosstalk. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-09 Ines Domínguez de la Cruz,Lluis Blanch,Guillermo M Albaiceta
-
Reply to Domínguez de la Cruz et al.: Little Big Issues in Brain-Lung Crosstalk. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-09 Dimitrios Georgopoulos
-
Clustering Pulmonary Hypertension Patients Using the Plasma Proteome. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-09 Athénaïs Boucly,Shanshan Song,Merve Keles,Dennis Wang,Luke S Howard,Marc Humbert,Olivier Sitbon,Allan Lawrie,A A Roger Thompson,Philipp Frank,Mika Kivimaki,Christopher J Rhodes,Martin R Wilkins
INTRODUCTION Patients with pulmonary hypertension are classified according to clinical criteria to inform treatment decisions. Knowledge of the molecular drivers of pulmonary hypertension might better inform treatment choice. METHODS Between 2013 and 2021, 470 patients with pulmonary hypertension, 136 disease controls and 59 healthy controls were enrolled as a discovery cohort. Plasma levels of 7288
-
Social Determinants of Health and Racial Disparities in Lung Function: Findings from NHANES 2007-2012. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-09 Amin Adibi,Christopher Carlsten,Emily P Brigham,Don D Sin,Peter Loewen,Mohsen Sadatsafavi
RATIONALE We hypothesized that the disproportionate impact of social determinants of health (SDoH) captured in survey data could help explain a larger proportion of racial gaps in lung function than previously reported. METHODS We defined a series of nested, increasingly healthy reference populations using data from NHANES 2007-2012. Starting with non-smokers without respiratory symptoms or diagnoses
-
Evaluating the Non-Malignancy Rate in the National Lung Screening Trial: Addressing Surgical Misclassification. Chest (IF 9.5) Pub Date : 2025-05-09 Christopher R Caruso,Roger Y Kim,Katharine A Rendle,Anil Vachani
-
The Impact of Healthcare Disparities on Lung Cancer Screening and Treatment. Chest (IF 9.5) Pub Date : 2025-05-09 Brett Bade,Saadia A Faiz,Miranda Tan,Aaron D Baugh,Mark Lavercombe,Ajay Sheshadri
From screening to treatment, the continuum of lung cancer care suffers from unequal access and delivery, with more vulnerable patients less able to receive high-quality care. Despite great advances in lung cancer care (e.g., screening and nodule programs to identify early-stage disease and immune-mediated and targeted therapies for advanced-stage disease), disparities persist both in the United States
-
Pregnancy Outcomes in 53 Female Lung Transplant Recipients. Chest (IF 9.5) Pub Date : 2025-05-09 Frank G Lee,Lisa A Coscia,Serban Constantinescu,Michael J Moritz
BACKGROUND Limited data exists to inform and appropriately counsel female lung transplant (LuT) recipients regarding post-transplant pregnancy. QUESTION What are the modifiable factors that impact pregnancy outcomes in female LuT recipients? STUDY DESIGN AND METHODS Retrospective observational analysis was performed on female LuT recipients who reported post-transplant pregnancies to the Transplant
-
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-08 Timothy E Weir, Helen James, Emily Carreiro, Margaret S Herridge
No Abstract
-
High rates of post-tuberculosis lung disease among persons successfully treated for drug-susceptible and resistant tuberculosis Thorax (IF 9.0) Pub Date : 2025-05-07 Russell R Kempker, Argita D Salindri, Teona Avaliani, Hardy Kornfeld, Sara C Auld, Nino Jakobia, Cheryl L Day, Arijita Subuddhi, Krista N Krish, Sergo Vashakidze, Zaza Avaliani, Leila Goginashvili, Cassandra Bryan, Adam Bernheim, Maia Kipiani, Matthew J Magee
Introduction Tuberculosis (TB) remains a critical global public health challenge, and there is an urgent need to improve the diagnosis and management of post-TB lung disease (PTLD). We aimed to compare end of treatment prevalence of PTLD among participants with and without drug-resistant TB and to evaluate the association between plasma cytokines and matrix metalloproteinases with lung damage. Methods
-
Future of academic respiratory medicine: near crisis point Thorax (IF 9.0) Pub Date : 2025-05-07 Steven Walker, Nick Maskell
A crisis is a time of intense difficulty, a turning point when an important change needs to take place. Here, we argue that the UK is approaching a critical point in clinical research capacity, following years of decline in medically trained research staff.1 The British Thoracic Society (BTS) respiratory consultant and trainee surveys (2024) highlighted the problems facing respiratory research. The
-
Drugs targeting novel pathways in pulmonary arterial hypertension. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-08 Olivier Sitbon,Athénaïs Boucly,Jason Weatherald,Fabrice Antigny,Christophe Guignabert,Mitja Jevnikar,Xavier Jaïs,Laura C Price,Martin R Wilkins,Roham T Zamanian,Laurent Savale,David Montani,Marc Humbert
Over the past three decades, several drugs have been developed to target three major dysfunctional pathways in PAH, including the prostacyclin, endothelin, and nitric oxide pathways. Despite these advances, PAH remains incurable, necessitating further drug discovery efforts. New therapies focus on previously untargeted pathways, especially the bone morphogenetic protein (BMP)/transforming growth factor-beta
-
Implementation of European National Driving Regulations for Obstructive Sleep Apnoea: challenges and recommendations. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-08 Walter T McNicholas,Ysbrand D van der Werf,Sarah Hartley,Pierre Philip,
BACKGROUND Obstructive sleep apnoea (OSA) carries an increased risk of motor vehicle accidents (MVA), which resulted in the European Commission introducing a legal directive (2014/85/EU) restricting driving in patients with moderate/severe OSA and sleepiness, unless effectively treated. We assessed the implementation of the directive in European Union (EU) member and non-member states. METHODS National
-
Practice Patterns and Patient Travel Distances for Lung Cancer Surgery in the United States: Analyses of the Veterans Health Administration and the National Cancer Database. Chest (IF 9.5) Pub Date : 2025-05-08 Steven Tohmasi,Daniel B Eaton,Nikki E Rossetti,Brendan T Heiden,Theodore S Thomas,Martin W Schoen,Ana A Baumann,Su-Hsin Chang,Yan Yan,Mayank R Patel,Whitney S Brandt,Bryan F Meyers,Benjamin D Kozower,Varun Puri
-
Defining Interstitial Lung Disease Education in Pulmonary Fellowship: A Mixed Methods Study: Defining ILD Education in Pulmonary Fellowship. Chest (IF 9.5) Pub Date : 2025-05-07 Samantha Irene King,Anna Neumeier,Bridget Graney,Maryl Kreider,Ryan Peterson,Tristan Huie
BACKGROUND Patients with interstitial lung disease (ILD) often receive care from general pulmonologists, as geographic and financial barriers limit access to specialized care centers. However, graduating pulmonary fellows lack confidence in managing patients with ILD. Refining ILD education in pulmonary fellowship could address this gap, but what trainees must learn is not currently defined. RESEARCH
-
Lung Cancer Screening Adherence in Centralized versus Decentralized Screening Programs A Meta-Analysis of U.S. Cohort Studies Among Individuals with Negative Baseline Results. Chest (IF 9.5) Pub Date : 2025-05-07 Elochukwu Ezenwankwo,Camden Jones,Duong Thuy Nguyen,Jan M Eberth
BACKGROUND With growing interest in a centralized approach to lung cancer screening (LCS), pooling current evidence to estimate its impact on annual adherence is essential for aligning practice with guideline recommendations. RESEARCH QUESTION Is participation in a centralized screening program associated with higher adherence rates compared to decentralized programs among individuals with negative
-
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-05 Antoine Kimmoun, Connor O'Brien, Vanessa Blumer, Florian A Wenzl, Janine Pöss, Uwe Zeymer, Jacob E Møller, Nadia Aissaoui, Shashank S Sinha, Alain Combes, Naoki Sato, Alessandro Sionis, Sabri Soussi, Susanna Price, Rhonda E Monroe, Rebecca Mathew, Alexandre Mebazaa
Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have shown that increasing survival rates in cardiogenic shock is challenging. Even the most successful trials show 5–15% reductions in mortality, and gains have been restricted to acute myocardial infarction cardiogenic shock, representing approximately 5% of the population with
-
Rethinking pulmonary arterial hypertension care: the role of dual therapy in patients with cardiovascular comorbidities. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-06 Clara Hjalmarsson,Sandeep Sahay
-
Pulmonary arterial hypertension and targeting pulmonary vascular remodelling: are we there yet? Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-06 James Lordan,Jason Weatherald
-
Reply to: Unravelling the physiology of exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-06 Bryce N Balmain,Tony G Babb
-
Unravelling the physiology of exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction. Eur. Respir. J. (IF 16.6) Pub Date : 2025-05-06 Ajay Kumar Jha
-
Trends in Medicare Spending on Drugs for Pulmonary Arterial Hypertension, 2012-2022. Chest (IF 9.5) Pub Date : 2025-05-05 Jenny A Shih,Charlie Lee,William B Feldman
-
The rising threat of predatory journals and paper mills in respiratory medicine and research Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-02 Joan B Soriano, Alberto Ruano-Ravina
No Abstract
-
Time T—to understand treatment response Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-01 Iwein Gyselinck, Helene Huts, Maarten De Vos, Wim Janssens
No Abstract
-
Alveolar Collapse in ARDS Causes Severe Lung Damage, but What About Liquid Resuscitation? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-02 Bo Liu
-
Reply to Liu: Alveolar Collapse in ARDS Causes Severe Lung Damage, but What About Liquid Resuscitation? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-02 Mayson L A Sousa,Bhushan H Katira,Sheena Bouch,Vanessa Hsing,Doreen Engelberts,Marcelo B P Amato,Martin Post,Laurent J Brochard
-
Anomalous Azygos Continuation of the Inferior Vena Cava and Bifemoral Veno-Venous Extracorporeal Membrane Oxygenation. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-05-02 Lorenzo Giosa,Nicholas Ioannou,Carla Goncalves,Filippo Palmesino,Christopher I S Meadows